The number of U.S. retail opioid prescriptions fell by 10.2% in 2017, including a 16.1% decline in high-dose prescriptions, according to a report released today by the IQVIA Institute for Human Data Science. The Centers for Disease Control and Prevention defines high-dose prescriptions as 90 morphine milligram equivalents or more per day. Total MME volume fell by 12%, or 23.3 billion, the largest annual drop in more than 25 years, according to the report. New opioid therapy starts fell 7.8%, while treatment starts for medication-assisted therapies nearly doubled to 82,000 prescriptions per month. The report also includes many other findings about drug spending, including that patients spent $57.8 billion in 2017 in out-of-pocket costs for medicines, including copays, coinsurance, payments during deductible phases of their insurance, or due to lack of insurance coverage.

Related News Articles

Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and…
Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that…
Headline
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,…